Lead Sponsor

Merck Sharp & Dohme LLC

Age

8 - 10 years

Sex

ALL

Healthy Volunteers

Yes

•Is healthy (based on a review of medical history and targeted physical examination) based on the clinical judgment of the investigator.
•Has participated in Protocol V419-007 and received a 3 + 1 Vaxelis® schedule or participated in Protocol V419-008 and received a 2 + 1 Vaxelis® schedule.
•The participant (or legally acceptable representative if applicable) provides written informed consent/assent for the study.

•Has a history of diagnosis (clinical, serological, or microbiological) of HBV infection.
•Has a known or suspected impairment of immunological function (e.g., human immunodeficiency virus (HIV), splenectomy).
•Has a known hypersensitivity to any component of the study vaccine.
•Has a known or suspected blood dyscrasias, leukemia, lymphomas of any type or other malignant neoplasms affecting the haematopoietic and lymphatic system.
•Has a bleeding disorder contraindicating intramuscular vaccinations.
•Has received any hepatitis B vaccine after participation in Protocol V419-007 or V419-008.
•Is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.

Related studies

NCT07417553 · Chronic Hepatitis B-related Liver Fibrosis

NCT02932150 · Chronic Hepatitis B

NCT07024641 · Hepatitis B Virus Infection

NCT05856890 · Hepatitis b Virus, Hepatitis B

NCT06671093 · Chronic Hep B, Chronic Hepatitis b, and more

A Hepatitis B Vaccine Challenge Study After Previous Vaxelis® Vaccination (V419-013)